{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:40:19Z","timestamp":1787139619912,"version":"build-2736575974"},"reference-count":38,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>This study aimed to assess the efficacy and safety of combining cemiplimab, an anti\u2013programmed cell death protein 1 (PD-1) antibody, with isatuximab, an anti-CD38 antibody, in relapsed or refractory extranodal natural killer\/T-cell lymphoma (R\/R ENKTL). The hypothesis was that CD38 blockade could enhance the antitumor activity of PD-1 inhibitors. Eligible patients received cemiplimab (250 mg on days 1 and 15) and isatuximab (10 mg\/kg on days 2 and 16) IV every 4 weeks for 6 cycles. Responders then received cemiplimab (350 mg) and isatuximab (10 mg\/kg) every 3 weeks for up to 24 months. The primary end point was the complete response (CR) rate based on the best response. Of 37 patients enrolled, the CR rate was 51% (19\/37), exceeding the primary end point of 40%, and the objective response rate was 65% (24\/37). After a median follow-up of 30.2 months (95% confidence interval [CI], 25.6-34.8 months), the median progression-free survival was 9.5 months (95% CI, 1.4-17.6 months), whereas the median overall survival had not yet been reached. Patients achieving CR received a median of 28 cycles (range, 4-33 cycles), and the median duration of response for responders (n = 24) was 29.4 months (95% CI, 15.4-43.4 months). Structural variations disrupting the 3\u2019-untranslated region of PD-L1 and high programmed death ligand 1 (PD-L1) expression were observed in responders. Most adverse events were mild (grade 1-2), with grade \u22653 events (32%) and no treatment-related deaths. The combination of isatuximab and cemiplimab demonstrated sustained antitumor activity and a manageable safety profile in R\/R ENKTL. This phase 2 trial is registered at www.clinicaltrials.gov as number NCT04763616.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024027109","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T16:23:17Z","timestamp":1741796597000},"page":"155-166","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed\/refractory NK\/T-cell lymphoma"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2776-4401","authenticated-orcid":false,"given":"Seok Jin","family":"Kim","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"},{"name":"2Department of Health Sciences and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3732-8707","authenticated-orcid":false,"given":"Jing Quan","family":"Lim","sequence":"additional","affiliation":[{"name":"3Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore, Singapore"},{"name":"4Oncology Academic Clinical Programme, Duke-National University Singapore Medical School, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0379-5297","authenticated-orcid":false,"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok-Hwan","family":"Yang","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8321-4113","authenticated-orcid":false,"given":"Sung Yong","family":"Oh","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0054-3641","authenticated-orcid":false,"given":"Yoon Seok","family":"Choi","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Hyun","family":"Jeong","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Oncology, Department of Internal Medicine, Ajou University School of Medicine, Suwon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3730-2777","authenticated-orcid":false,"given":"Sung Nam","family":"Lim","sequence":"additional","affiliation":[{"name":"10Department of Internal Medicine, Haeundae Baek Hospital, Inje University College of Medicine, Busan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhun","family":"Cho","sequence":"additional","affiliation":[{"name":"11Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bon","family":"Park","sequence":"additional","affiliation":[{"name":"2Department of Health Sciences and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Ju","family":"Ryu","sequence":"additional","affiliation":[{"name":"2Department of Health Sciences and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghyun","family":"Choi","sequence":"additional","affiliation":[{"name":"12Chemical and Biological Integrative Research Center, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-8901","authenticated-orcid":false,"given":"Yoon","family":"Park","sequence":"additional","affiliation":[{"name":"12Chemical and Biological Integrative Research Center, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry May","family":"Huifen Lim","sequence":"additional","affiliation":[{"name":"3Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Ayuni","family":"Binte Muhammad Taib","sequence":"additional","affiliation":[{"name":"3Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choon Kiat","family":"Ong","sequence":"additional","affiliation":[{"name":"3Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore, Singapore"},{"name":"4Oncology Academic Clinical Programme, Duke-National University Singapore Medical School, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0366-5505","authenticated-orcid":false,"given":"Soon Thye","family":"Lim","sequence":"additional","affiliation":[{"name":"13Director's Office, National Cancer Centre Singapore, Singapore, Singapore"},{"name":"14Office of Education, Duke-National University Singapore Medical School, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-0466","authenticated-orcid":false,"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"},{"name":"2Department of Health Sciences and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2025071011262350600_bib1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1011144911781","article-title":"CHOP followed by involved field radiation: is it optimal for localized nasal natural killer\/T-cell lymphoma?","volume":"12","author":"Kim","year":"2001","journal-title":"Ann Oncol"},{"issue":"17","key":"2025071011262350600_bib2","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","article-title":"Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project","volume":"113","author":"Au","year":"2009","journal-title":"Blood"},{"issue":"33","key":"2025071011262350600_bib3","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"35","key":"2025071011262350600_bib4","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study","volume":"27","author":"Kim","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025071011262350600_bib5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13045-018-0687-0","article-title":"Treatment of localized extranodal NK\/T cell lymphoma, nasal type: a systematic review","volume":"11","author":"Kim","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"23","key":"2025071011262350600_bib6","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type","volume":"131","author":"Yamaguchi","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2025071011262350600_bib7","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/annonc\/mdx316","article-title":"Beyond first-line non-anthracycline-based chemotherapy for extranodal NK\/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease","volume":"28","author":"Lim","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"2025071011262350600_bib8","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.bbmt.2018.07.034","article-title":"Allogeneic stem cell transplantation for patients with natural killer\/T cell lymphoid malignancy: a multicenter analysis comparing upfront and salvage transplantation","volume":"24","author":"Jeong","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"17","key":"2025071011262350600_bib9","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2025071011262350600_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2025071011262350600_bib11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.4143\/crt.2018.191","article-title":"Comparison of efficacy of pembrolizumab between Epstein-Barr virus\u2012positive and\u2012negative relapsed or refractory non-Hodgkin lymphomas","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res Treat"},{"issue":"2","key":"2025071011262350600_bib12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4143\/crt.2023.1042","article-title":"Pembrolizumab for patients with relapsed or refractory extranodal NK\/T-cell lymphoma in Korea","volume":"56","author":"Lee","year":"2024","journal-title":"Cancer Res Treat"},{"issue":"10","key":"2025071011262350600_bib13","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1007\/s00277-024-05739-3","article-title":"Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK\/T cell lymphoma","volume":"103","author":"Yoon","year":"2024","journal-title":"Ann Hematol"},{"issue":"3","key":"2025071011262350600_bib14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/hon.3116","article-title":"Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural killer\/T cell lymphoma: a retrospective study","volume":"41","author":"Tian","year":"2023","journal-title":"Hematol Oncol"},{"issue":"1","key":"2025071011262350600_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","article-title":"Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)","volume":"6","author":"Tao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"24","key":"2025071011262350600_bib16","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: an open-label phase 2 study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"issue":"16","key":"2025071011262350600_bib17","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.02367","article-title":"Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer\/T-cell lymphoma (GEMSTONE-201): results from a single-arm, multicenter, phase II study","volume":"41","author":"Huang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025071011262350600_bib18","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","article-title":"CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Discov"},{"issue":"15","key":"2025071011262350600_bib19","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025071011262350600_bib20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hon.3089","article-title":"A phase 1\/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma","volume":"41","author":"Carlo-Stella","year":"2023","journal-title":"Hematol Oncol"},{"issue":"8","key":"2025071011262350600_bib21","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00277-015-2359-2","article-title":"CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK\/T cell lymphoma, nasal type","volume":"94","author":"Wang","year":"2015","journal-title":"Ann Hematol"},{"issue":"27","key":"2025071011262350600_bib22","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025071011262350600_bib23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025071011262350600_bib24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00262-017-1987-x","article-title":"Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy","volume":"66","author":"Nagato","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2025071011262350600_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41379-019-0392-8","article-title":"Immune subtyping of extranodal NK\/T-cell lymphoma: a new biomarker and an immune shift during disease progression","volume":"33","author":"Cho","year":"2020","journal-title":"Mod Pathol"},{"issue":"9","key":"2025071011262350600_bib26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/ajh.26636","article-title":"A genomic-augmented multivariate prognostic model for the survival of natural-killer\/T-cell lymphoma patients from an international cohort","volume":"97","author":"Lim","year":"2022","journal-title":"Am J Hematol"},{"issue":"12","key":"2025071011262350600_bib27","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41375-020-1000-0","article-title":"Whole-genome sequencing identifies responders to pembrolizumab in relapse\/refractory natural-killer\/T cell lymphoma","volume":"34","author":"Lim","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"2025071011262350600_bib28","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41375-019-0380-5","article-title":"Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas","volume":"33","author":"Kataoka","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"2025071011262350600_bib29","doi-asserted-by":"crossref","first-page":"793","DOI":"10.7150\/jca.17766","article-title":"Overexpression of MYC and BCL2 predicts poor prognosis in patients with extranodal NK\/T-cell lymphoma, nasal type","volume":"8","author":"Wang","year":"2017","journal-title":"J Cancer"},{"issue":"3","key":"2025071011262350600_bib30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ccell.2020.02.005","article-title":"Genomic and transcriptomic characterization of natural killer T cell lymphoma","volume":"37","author":"Xiong","year":"2020","journal-title":"Cancer Cell"},{"issue":"8","key":"2025071011262350600_bib31","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1007\/s00277-024-05698-9","article-title":"Analysis of mutation profiles in extranodal NK\/T-cell lymphoma: clinical and prognostic correlations","volume":"103","author":"Chang","year":"2024","journal-title":"Ann Hematol"},{"issue":"8","key":"2025071011262350600_bib32","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.ymthe.2022.05.003","article-title":"LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation","volume":"30","author":"Sung","year":"2022","journal-title":"Mol Ther"},{"issue":"1","key":"2025071011262350600_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"S1","key":"2025071011262350600_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5045\/br.2022.2022037","article-title":"Basic immunohistochemistry for lymphoma diagnosis","volume":"57","author":"Cho","year":"2022","journal-title":"Blood Res"},{"issue":"11","key":"2025071011262350600_bib35","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","article-title":"Oncogenic activation of STAT3 pathway drives PD-L1 expression in natural killer\/T cell lymphoma","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025071011262350600_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-020-01020-y","article-title":"Daratumumab monotherapy for patients with relapsed or refractory natural killer\/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study","volume":"14","author":"Huang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2025071011262350600_bib37","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2352-3026(19)30283-2","article-title":"Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell project","volume":"7","author":"Fox","year":"2020","journal-title":"Lancet Haematol"},{"key":"2025071011262350600_bib38","first-page":"100126","article-title":"Comprehensive analysis of peripheral T-cell and natural killer\/T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia","volume":"10","author":"Yoon","year":"2021","journal-title":"Lancet Reg Health West Pac"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/2\/155\/2402422\/blood_bld-2024-027109-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/2\/155\/2402422\/blood_bld-2024-027109-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T15:26:34Z","timestamp":1752161194000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/2\/155\/536007\/Efficacy-of-combined-CD38-and-PD-1-inhibition-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027109","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,10]]},"published":{"date-parts":[[2025,7,10]]}}}